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doi:10.1016/j.jtcvs.2007.04.020bjectives: Aortic stentless pericardial valves were introduced into clinical practice
o combine properties of both stentless and pericardial prostheses. The aim of this
ingle-center retrospective study was to assess midterm clinical and hemodynamic
esults of aortic valve replacement with the Sorin Pericarbon Freedom stentless
ioprosthesis.
ethods: From July 1999 through November 2005, 130 consecutive patients (73
56.1%] male patients) underwent aortic valve replacement with the Sorin Pericar-
on Freedom bioprosthesis at our institution. Mean age was 76  5 years (range,
2-86 years), and associated procedures were performed in 50 (38.4%) patients; of
hese, 41 were coronary artery bypass grafts. Surgical intervention under urgent/
mergency conditions and reoperations were performed in 18 (13.8%) and 7 (5.3%)
atients, respectively. Mean crossclamp and cardiopulmonary bypass times were
2  24 and 125  40 minutes, respectively. All patients underwent clinical and
chocardiographic follow-up (100% complete), and the total cumulative follow-up
as 324 patient/years (mean, 2.5  1.8; range, 6 months–7 years).
esults: Overall hospital mortality was 8.4%. Overall patient survival was 63% 
% and 50%  10% at 5 and 7 years, respectively. Late deaths occurred in 23
atients, and 6 of them were valve related (1.8% patient/years). Freedom from
alve-related death and reoperation was 91%  4% and 94%  4%, respectively,
t 7 years. No structural valve deterioration was observed. Endocarditis, thrombo-
mbolism, and hemorrhagic complications occurred in 2 (0.6% patient/years), 1
0.3% patient/years), and 1 (0.3% patient/years) patients, respectively. Mean
ransprosthetic gradients for valve sizes 23, 25, and 27 were 12.1 3.8, 10.8 3.8,
nd 9  3.1 mm Hg, respectively.
onclusions: The Sorin Pericarbon Freedom stentless bioprosthesis provides
ood early and midterm results in terms of hemodynamic performance, survival,
nd freedom from valve-related complications.
tentless aortic bioprostheses appear to provide improved transvalvular gradi-
ents and increased orifice areas and survival rates compared with stented
valves.1 Furthermore, pericardial aortic stented valves have demonstrated
xcellent durability, freedom from primary tissue failure, and freedom from pros-
hetic endocarditis.2,3
The Sorin Pericarbon Freedom (SPF; Sorin Biomedica, Saluggia, Italy) is a
tentless pericardial valve prosthesis made of two sheets of pericardium sutured
ogether without any fabric reinforcement and prepared with a postfixation treatment
ith homocysteic acid, which neutralizes residues of unbound aldehyde groups left
fter the fixation process. This peculiar design, the anticalcification treatment, and
he absence of any synthetic material except for sutures should provide good results
The Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 2 491
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A
CDn terms of hemodynamics, freedom from structural valve
eterioration, and freedom from prosthetic valve endocar-
itis. The aim of this retrospective and single-center study
as to assess early and midterm results of aortic valve
eplacement (AVR) with the SPF bioprosthesis.
aterials and Methods
tudy Population
rom July 1999 through December 2005, 130 consecutive patients
nderwent AVR with the SPF bioprosthesis at our institution.
emographic and clinical preoperative data of the study popula-
ion are listed in Table 1.
Selection criteria for the implantation of the SPF bioprosthesis
ere as follows: age older than 65 years, contraindication to oral
nticoagulant therapy, request for a biologic valve by the patient,
mall aortic annulus, and surgeon’s preferences. Furthermore, SPF
ioprostheses were intentionally implanted in patients with ab-
cesses of the aortoventricular junction. The contraindications for
he implantation of the SPF were severe calcification of the aortic
nnulus and aortic root aneurysm.
urgical Intervention
urgical intervention was performed during moderate hypothermia
n all patients. Myocardial protection was obtained by using ret-
Abbreviations and Acronyms
AVR aortic valve replacement
SPF  Sorin Pericarbon Freedom
ABLE 1. Preoperative patient characteristics
n %
ge (y) 76  5 (range, 42-86)
ex Male: 73
Female: 57
56
44
istory of smoking 44 34
ypertension 101 78
ypercholesterolemia 61 47
iabetes 30 23
istory of CVA 12 9
hronic renal failure 8 6
acterial endocarditis 8 6
evere COPD 15 12
revious surgical intervention 7 5
trial fibrillation 21 16
F (%) 58  14
rgent/emergency 18 14
YHA class I: 6 5
II: 23 18
III: 81 62
IV: 20 15
dditive EUROscore 9.2  2.2
VA, Cerebrovascular accident; COPD, chronic obstructive pulmonary
oisease; EF, ejection fraction; NYHA, New York Heart Association.
92 The Journal of Thoracic and Cardiovascular Surgery ● Auguograde and selective antegrade cardioplegia. The SPF bioprosthe-
is was implanted with 3 continuous 4-0 polypropylene sutures
oth for the inflow and the outflow rim.
Valve sizes 21, 23, 25, and 27 were implanted in 1 (0.8%), 57
43.8%), 54 (41.6%), and 18 (13.8%) patients, respectively.
Fifty-one associated procedures were performed in 50 (38.4%)
atients: 41 coronary artery bypass graftings, 4 mitral valve re-
airs, 2 mitral valve replacements, 3 replacements of the ascending
orta, and 1 patent foramen ovale closure. Mean aortic crossclamp
imes were 82 24 and 79 18 minutes for the whole population
nd for isolated AVR, respectively. Mean cardiopulmonary bypass
imes were 125  40 and 122  36 minutes for the whole
opulation and for isolated AVR, respectively. Indications for
VR were as follows: calcific aortic stenosis in 99 (76.2%), aortic
egurgitation in 10 (7.7%), endocarditis in 8 (6.2%), rheumatic
isease in 5 (3.8%), prosthesis malfunction in 6 (4.6%), and
ongenital bicuspid valve in 2 (1.5%) patients.
After implantation, oral anticoagulant therapy was prescribed
n all patients and discontinued 3 months later; this is the routine
nticoagulation protocol for all bioprostheses at our institution.
cetylsalicylic acid, 100 mg daily, or ticlopidine, 250 mg daily,
ere then used as antiplatelet agents. Permanent anticoagulant
herapy in a dose adjusted to achieve a target international nor-
alized ratio of 2.0 to 3.0 was prescribed in 6 (5%) patients with
hronic atrial arrhythmias.
ollow-up
ll patients underwent scheduled visits at our outpatient clinic 1,
, and 12 months after the operation and on a yearly basis there-
fter. Clinical follow-up was 100% complete. Mean clinical
ollow-up time was 2.5 1.8 years (range, 6 months-7 years), and
otal cumulative follow-up was 324 patient/years.
From January through September 2006, all of the 96 survivors
74% of the initial study population) were purposely asked to
ndergo an echocardiographic evaluation. Echocardiography was
erformed at our institution by the same physician in 70 (72.9%)
atients. Twenty-six (27.1%) patients underwent evaluation at
ifferent outside laboratories. Echocardiograms from outside lab-
ratories were sent to us by patients or by the patients’ referring
ardiologists.
Mean echocardiographic follow-up time was 37.1 20 months
range, 9.4-82.2 months). Echocardiography was performed with
n iE 33 cardiac ultrasound scanner (Royal Philips Electronics,
msterdam, The Netherlands) according to the American Society
f Echocardiography guidelines. Peak and mean transvalvular
ressure gradients were derived by using the modified Bernoulli
quation, and the effective orifice area was calculated with the
ontinuity equation.
Morbidity and fatal valve-related events were categorized as
esulting from structural valve deterioration, nonstructural valve
ysfunction, thromboembolism, prosthetic valve endocarditis,
emorrhagic complication, reoperation, valve-related mortality, or
ardiac-related mortality according to the Society of Thoracic
urgeons and American Association for Thoracic Surgery guide-
ines for reporting morbidity and mortality after cardiac valvular
perations.4
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A
CDtatistical Analysis
ontinuous data are expressed as means  1 standard deviation.
ategoric data are expressed as percentages. Survival analyses
ith the Kaplan–Meier method were used to estimate survival and
reedom from valve-related adverse events. Statistical analysis was
erformed with the SPSS statistical package (SPSS, Inc, Chicago,
ll). The incidence of late adverse events is shown by using
inearized rates (events per 100 patient/years).
esults
perative mortality was 8.4% (11 patients). Among these,
ombined coronary artery bypass grafts and mitral valve
eplacement were performed in 8 patients and 1 patient,
espectively. Causes of early deaths were acute myocardial
nfarction in 4 patients, multiorgan failure in 3 patients,
epsis in 2 patients, and stroke and acute respiratory distress
yndrome in 1 patient each.
Four patients had a complete atrioventricular block and
eeded permanent pacemaker implantation before hospital
ischarge.
The overall patient survival rate was 63%  6% and
0%  10% at 5 and 7 years, respectively (Figure 1). There
ere 23 late deaths (7.1% patient/years). Causes and linear-
zed rates of late deaths are listed in Table 2.
Reoperations were performed in 3 patients (0.9% patient/
ears) during the follow-up period. Causes of reoperation
ere as follows: endocarditis with annular abscess and
onsequent valve distortion, nonstructural valve deteriora-
ion (paravalvular leak with severe regurgitation), and cor-
nary artery disease with mild paravalvular leak. In the
atter case, the valve was not replaced but once again fixed
n place.
igure 1. Kaplan–Meier survival after aortic valve replacement
ith the Sorin Pericarbon Freedom stentless bioprosthesis (SPF).
illed circles represent estimated survival for the 76-year-old
ohort (56% male subjects) in Italy in 2003 (data from the Italian
nstitute of Statistics, www.istat.it). Vertical lines represent 95%
onfidence intervals of survival for the SPF cohort. s
The Journal of ThoracicFreedom from valve-related death (Figure 2) and reop-
ration (Figure 3) was 91%  4% and 94%  4%, respec-
ively, at 7 years.
Endocarditis, thromboembolism, and hemorrhagic com-
lications occurred in 2 patients (0.6% patient/years), 1
atient (0.3% patient/years), and 1 patient (0.3% patient/
ears), respectively. One patient had the SPF bioprosthesis
xplanted because of a prosthetic valve endocarditis (Strep-
ococcus bovis) 1 month after the operation. Another patient
ith preoperative endocarditis died of acute septic shock 2
onths after the operation, and at autopsy, the aortic annu-
us and the bioprosthesis appeared totally destroyed. A third
atient underwent a major cerebrovascular accident. This
atient had a clinical preoperative history of nonsignificant
arotid artery disease and of diffuse peripheral arterial ath-
rosclerosis. Lastly, another patient, during anticoagulant
herapy, had gastric bleeding requiring homologous blood
ransfusions.
ABLE 2. Causes and linearized rates of late deaths
ause of late deaths No. (% patient/y)
alve related
Sudden/unexplained/unexpected 4 (1.2)
Endocarditis 1 (0.3)
Hemorrhage 1 (0.3)
ardiac related
CHF 5 (1.5)
AMI 2 (0.6)
oncardiac 8 (2.4)
nknown 2 (0.6)
HF, Congestive heart failure; AMI, acute myocardial infarction.
igure 2. Kaplan–Meier freedom from valve-related death after
ortic valve replacement with the Sorin Pericarbon Freedom
tentless bioprosthesis.
and Cardiovascular Surgery ● Volume 134, Number 2 493
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A
CDMild aortic regurgitation was found in 4 patients (1.2%
atient/years); they are asymptomatic and scheduled to un-
ergo an echocardiogram control every year.
Peak and mean transvalvular gradients, effective orifice
rea, and effective orifice area index are shown in Table 3
or valve sizes 23, 25, and 27 because only 1 patient
eceived a size 21 prosthesis.
iscussion
owadays, several different models of aortic valve prosthe-
es are available on the market. Choice depends on several
ssues: patient age, nature of the aortic valve disease, pres-
nce of annulus calcification, contraindication to oral anti-
oagulant therapy, and patient and surgeon preferences.
Tissue valves are commonly indicated in patients older
han 65 years because no data support implantation in
ounger patients.5 Among tissue aortic valve prostheses, 2
ignificant distinctions need to be made: between porcine
nd pericardial valves and between stented and stentless
alves.
The first porcine valves were implanted almost 40 years
go,6 whereas the first pericardial prostheses were intro-
uced at the end of the 1970s. The latter initially showed a
ignificantly higher incidence of primary failure than por-
ine xenografts and were temporarily abandoned.7 They
ere reintroduced in 1981 and approved by the US Food
nd Drug Administration in 1991, and since then, thousands
f stented pericardial valves have been implanted in the
ortic position with excellent results. Gao and colleagues3
eviewed their long-term experience with 518 stented por-
ine and 1021 stented pericardial valves. They found that
igure 3. Kaplan–Meier freedom from reoperation after aortic
alve replacement with the Sorin Pericarbon Freedom stentless
ioprosthesis.he pericardial valve had a significantly higher rate of 10- t
94 The Journal of Thoracic and Cardiovascular Surgery ● Auguear actuarial freedom from explantation when compared
ith the porcine prosthesis (97% vs 90%, P  .04).
The difference between stented and stentless valves is
rimarily based on hemodynamic performance. Theoreti-
ally, the absence of a stent and of a sewing ring in a
tentless valve should provide more space available for
lood flow and result in lower transvalvular gradients and
arger effective orifice areas. Many studies have demon-
trated stentless valves’ superiority in terms of hemodynam-
cs,1,8,9 survival from valve-related mortality,10 and coro-
ary blood flow11 when compared with stented xenografts.
owever, recent studies have shown no significant differ-
nces in hemodynamic performance between stentless and
ast-generation porcine aortic valve prostheses.12,13
The SPF bioprosthesis is a stentless pericardial valve
ntroduced into clinical practice at the end of the 1990s. Its
tentless design and pericardium could play a synergic role,
ixing together the advantages of both pericardial and
tentless valves to extend valve durability and to improve
emodynamic performance.
We reviewed our 7-year experience with the SPF bio-
rosthesis, and to the best of our knowledge, this is the first
edium-term report of this prosthesis.
There are 3 different implantation techniques: continu-
us polypropylene sutures, interrupted simple sutures, and
nterrupted mattress sutures. There are no hemodynamic
ifferences among these 3 techniques.14
Our preferred implantation technique is with 3 continu-
us sutures for both the inflow and the outflow rim, which
rovides reduced crossclamp times, as previously described
y Beholz and associates.15
In our experience we did not find any structural valve
eterioration, and in the 3 explanted valves, the leaflets were
ndamaged and without any sign of calcification.
Freedom from valve-related mortality was 91%  4% at
years (6 patients). Although this might appear to be rather
ow, one must take into consideration that 4 of 6 deaths were
udden/unexpected/unexplained, and 1 was due to a mas-
ive hemorrhage during reoperation. Furthermore, there are
nly few patients at risk after 5 years, and this fact inevi-
ably causes a quick decrease of the Kaplan–Meier curve.
Nevertheless, the slope of the survival curve is similar to
ABLE 3. Hemodynamic data
Valve size
23 25 27
OA (cm2) 1.7  0.6 2.1  0.7 2.3  0.5
OAI (cm2/m2) 0.98 0.08 1.15  0.11 1.21  0.09
eak gradient (mm Hg) 21 7.4 19.5  5.8 14 2.9
ean gradient (mm Hg) 12.1 3.8 10.8  3.8 9 3.1
OA, Effective orifice area; EOAI, effective orifice area index.hat of the estimated survival of the cohort from the Italian
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A
CDopulation matched for age and sex. The difference between
he 2 curves is due only to the early mortality of the SPF
ohort; this could mean that if a patient survives the oper-
tion and is successfully discharged, his life expectancy
ecreases over time in the same way as that of the general
opulation.
The hemodynamics of the SPF bioprosthesis, in terms of
ransvalvular gradients and effective orifice areas, have been
hown to be similar to those of other routinely used stentless
alves. Borger and coworkers1 from Toronto, in a series of
10 stentless valves (Toronto SPV and Freestyle), reported
he following midterm hemodynamic data: effective orifice
rea, 1.67  0.67 cm2; peak gradient, 17  10 mm Hg; and
ean gradient, 9  5 mm Hg.
imitations of the study
imitations owing to the retrospective design of the study
re present. Because of the poor life expectancy of patients
n their seventh or eighth decade of life with important
omorbidities, patients at risk decrease with time indepen-
ently from valve-related events.
Survival and event-free curves have few patients beyond
years. Continued follow-up will be necessary to assess
esults at time points during which prosthesis failure is more
ikely.
Echocardiography was not performed by the same phy-
ician and with the same machine.
Preoperative and discharge echocardiographic data are
ot available for all patients, and thus the evaluation of
emodynamic performance development over time was not
ossible.
The recently published American College of Cardiology
ACC)/American Heart Association (AHA) Guidelines for
he management of patients with valvular heart disease16
tate that routine annual echocardiograms are not indicated
n the absence of a change in the clinical status in patients
ith a bioprosthetic valve (class III, level of evidence C)
ecause the expectation of structural valve deterioration in
his time period is low.
onclusions
he SPF stentless bioprosthesis appears to be a good option
or AVR in elderly patients and in those with contraindica-
ions to oral anticoagulant drugs. It provided good results in
erms of valve durability and freedom from valve-related
omplications. Echocardiographic data showed that the he-
The Journal of Thoracicodynamic performance of the SPF bioprosthesis is excel-
ent and overlaps that of other commercially available stent-
ess bioprostheses.
We thank Paul Marcucci for his assistance in manuscript revi-
ion and Irene Bolgan for help in the statistical analysis of the data.
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